Tafamidis meglumine

Drug Profile

Tafamidis meglumine

Alternative Names: Fx-1006A; FX1006A; PF-06291826; PF-6291826; Tafamidis; Vyndaqel

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator FoldRx Pharmaceuticals
  • Developer Pfizer
  • Class Benzoxazoles; Carboxylic acids; Chlorobenzenes; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy; Cardiomyopathies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy
  • Phase III Cardiomyopathies

Most Recent Events

  • 04 Aug 2017 Phase-III development for Cardiomyopathy is ongoing in the European Union and USA (NCT01994889), (Pfizer pipeline, May 2017)
  • 06 Jun 2017 Tafamidis meglumine receives Fast Track designation for Cardiomyopathy [PO,Capsule] in USA
  • 12 Apr 2017 Pfizer re-initiates enrolment in the phase III ATTR-ACT trial for Cardiomyopathy (Transthyretin amyloid cardiomyopathy) in USA, United Kingdom, Belgium, Netherlands, Czech Republic, Germany, Sweden, Spain, France, Italy and Japan (NCT01994889)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top